Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9836179 | 0.88 | IDO1 (0.53) | LMNAMAPTIDO1CYP11B1CYP11B2 | |
| SCHEMBL9077581 | 0.85 | IDO1 (0.47) | LMNAMAPTIDO1CYP11B1CYP11B2 | |
| SCHEMBL27999214 | 0.82 | CYP19A1 (0.50) | LMNAMAPTIDO1CYP11B1CYP11B2 | |
| SCHEMBL20777541 | 0.78 | IDO1 (0.53) | LMNAMAPTIDO1CYP11B1CYP11B2 | |
| SCHEMBL9196161 | 0.78 | IDO1 (0.43) | LMNAMAPTIDO1CYP11B1CYP11B2 | |
| SCHEMBL2463222 | 0.78 | IDO1 (0.56) | LMNAMAPTIDO1CYP11B1CYP11B2 | |
| SCHEMBL9760105 | 0.78 | IDO1 (0.41) | LMNAMAPTIDO1CYP3A4CYP1A2 | |
| Hydrochloric Acid SCHEMBL20774395 | 0.77 | IDO1 (0.51) | LMNAMAPTIDO1CYP11B1CYP11B2 | |
| SCHEMBL9191692 | 0.77 | CYP19A1 (0.43) | MAPTIDO1CYP3A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27626083 | 0.76 | IDO1 (0.54) | LMNAMAPTIDO1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687277-B1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-04 | — | — | EP | disclosed |
| US-9115084-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-08-25 | — | — | US | disclosed |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-12 | — | — | US | disclosed |
| US-8450486-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-8071612-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110124673-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-05-26 | — | — | US | disclosed |
| US-7855207-B2 | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | JANSSEN-CILAG (FR) | 2007-03-29 | — | — | US | disclosed |
| EP-1687277-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-09 | — | — | EP | disclosed |
| EP-1019395-B1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-30 | — | — | EP | disclosed |
| EP-1106610-A1 | Farnesyl transferase inhibiting 2-quinolone derivatives | Janssen Pharmaceutica N.V. (BE) | 2001-06-13 | — | — | EP | disclosed |
| EP-1019395-A1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-19 | — | — | EP | disclosed |
| WO-1997016443-A1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |
| US-5612354-A | CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-18 | — | — | US | disclosed |
| US-5441954-A | Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells | JANSSEN PHARMACEUTICA N. V. (BE) | 1995-08-15 | — | — | US | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5268380-A | Therapy for keratinization in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-07 | — | — | US | disclosed |
| US-5185346-A | Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents | HANSSEN PHARMACEUTICA (BE) | 1993-02-09 | — | — | US | disclosed |
| EP-0371564-A2 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072842-A1 | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors | PARP1, PARP6, PARP2 | LMNA 180/4885MAPT 2275/4885IDO1 2325/4885 |
| US-20110124673-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | LMNA 111/4885MAPT 2886/4885IDO1 1680/4885 |
| US-20130237528-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | LMNA 111/4885MAPT 2886/4885IDO1 1680/4885 |
| US-20120046274-A1 | 6-ALKENYL AND 6-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP6 | LMNA 111/4885MAPT 2886/4885IDO1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.